(NASDAQ: MGTX) Meiragtx Holdings's forecast annual revenue growth rate of -29.76% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.46%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.3%.
Meiragtx Holdings's revenue in 2026 is $397,501,000.On average, 9 Wall Street analysts forecast MGTX's revenue for 2026 to be $5,642,622,058, with the lowest MGTX revenue forecast at $141,183,204, and the highest MGTX revenue forecast at $18,818,664,636. On average, 8 Wall Street analysts forecast MGTX's revenue for 2027 to be $14,064,536,334, with the lowest MGTX revenue forecast at $6,821,069,619, and the highest MGTX revenue forecast at $26,171,716,410.
In 2028, MGTX is forecast to generate $10,198,805,745 in revenue, with the lowest revenue forecast at $4,706,490,976 and the highest revenue forecast at $15,451,397,196.